Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA

Behind the stellar launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug make it more complicated to pull it from the market if we find out next year that it doesn’t work?

Read the full article here

Related Articles